GlassScriptPhysician profile
Hannah K Baugh
NPI 1174057376
$5,895.96
in general payments reported to CMS, 2019-2025
39 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $1,211 · 2023: $1,142 · 2024: $1,318 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $853.81 | 2021-2025 | |
| Amgen INC. | $649.50 | 2021-2025 | Otezla, Repatha, Aimovig |
| Abbvie INC. | $590.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $443.70 | 2022-2025 | Rexulti |
| Abbott Laboratories | $368.73 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $280.54 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $271.53 | 2021-2024 | Mounjaro, Emgality, Reyvow |
| Glaxosmithkline, LLC. | $232.72 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.41 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $183.04 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $170.98 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $161.32 | 2021-2025 | Trintellix |
| Lundbeck LLC | $158.94 | 2022-2025 | Rexulti |
| Dexcom, INC. | $156.92 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $137.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Baugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.